Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of QL1101 vs EU-Avastin in Healthy Volunteers
NCT06232902Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QL1101 in solid tumor (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Area Under the Curve from time zero to infinity at 99 days and Maximum Concentration at 99 days. Started Jun 2024; status: completed.
02
Drugs
QL1101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06232902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232902.